Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00041652 · ClinicalTrials.gov registry record · Phase 1
Safety Study of hMN14 to Treat Either Colorectal or Breast Cancer
A Phase 1 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT00041652 is a Phase 1 study that has completed, run by Gilead Sciences. The registered enrollment target is 30 participants.
The verdict
NCT00041652, a Phase 1 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this trial is to determine the safety of hMN14 at different dose levels in the treatment of either colorectal or breast cancer.
Interventions
- DRUG hMN14 (labetuzumab)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2000-02 |
| Est. Completion | 2003-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00041652
The ClinicalTrials.gov registry entry for NCT00041652 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which hMN14 (labetuzumab) is the first listed.
NCT00041652 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00041652 about?
NCT00041652 is a clinical study titled "Safety Study of hMN14 to Treat Either Colorectal or Breast Cancer". The purpose of this trial is to determine the safety of hMN14 at different dose levels in the treatment of either colorectal or breast cancer.
What is the current status of trial NCT00041652?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2000-02. Estimated completion is 2003-06.
What interventions are being tested in trial NCT00041652?
The interventions under investigation include: hMN14 (labetuzumab) (DRUG).
Who is sponsoring clinical trial NCT00041652?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.